| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. | Drug Metab Dispos | 2010 | 0.79 |
| 2 | The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. | Cancer Chemother Pharmacol | 2013 | 0.76 |
| 3 | JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. | Leuk Lymphoma | 2008 | 0.75 |